Pappas Ventures Names Eric Linsley Managing Partner
Pappas Ventures has promoted Eric Linsley to managing partner.
Linsley, who joined the firm in 2000, has led investments in Peninsula Pharmaceuticals, acquired by Johnson & Johnson; Cerexa, acquired by Forest Laboratories; and Panacos Pharmaceuticals, which executed a successful reverse merger with VI Technologies.
Recently, he and the VC firm's founder Art Pappas led the team that closed on Pappas Ventures IV, a $102 million venture capital fund focused on the life sciences sector. Pappas Ventures IV is investing primarily in product-oriented biopharmaceutical companies, with a secondary focus on medical technologies. The new fund has, to date, invested in three portfolio companies and is actively seeking additional opportunities.
From 1991 to 1997, Linsley worked as an investment professional with Ampersand Ventures. Immediately prior to joining Pappas, he served as CFO of TriPath Imaging, a medical device company that was acquired in 2006 by Becton Dickinson.
He is currently a director of BaroSense, BioSyntech, Cequent Pharmaceuticals, and FlowCardia. He is also a board observer at LipoScience and Anthera Pharmaceuticals.
Tennessee Biotechnology Association Names New Board Members
The Tennessee Biotechnology Association has named several new members to its board:
• Richard Magid, vice president of the University of Tennessee Research Foundation at the UT Health Science Center;
• Bob Morris, a partner with the Butler Snow law firm;
• Kenneth Moss, president and managing partner of Frazier, Barnes & Associates;
• Jeff Smith, a partner in Ernst & Young’s Nashville office; and
• Ken Woody, president of Innova, a venture capital firm in Memphis;
Julia Schueler to Lead BioRegion Rhine-Neckar-Triangle Association
Julia Schueler has been selected to lead Germany's BioRegion Rhine-Neckar-Triangle Association.
Schueler most recently worked at the Ernst & Young Life Sciences Center in Mannheim, Germany, where she was responsible for the annual German Biotechnology Report and data analysis on the global biotech industry.
Schueler replaces Ernst-Dieter Jarasch, who is retiring. He has served as managing director of the association since its inception in 1996.